Irbesartan

Routes
Oral (PO)
Half-Life (t½)
PO: 14h
Formula
C25H28N6O
Molecular Weight
428.53 g/mol
PubChem CID
3749
Aliases
Avapro

Pharmacological Mechanism

AT1 receptor blocker — strong renoprotection signal in IDNT trial for diabetic nephropathy. Once-daily dosing.

Half-Life & Elimination Curve (PO: 14h)

100%50%25%12.5%0%0h0×t½14h1×t½28h2×t½42h3×t½56h4×t½70h5×t½0×t½ (0h): 100% remaining (~1.34 mg/L)1×t½ (14h): 50% remaining (~0.668 mg/L)2×t½ (28h): 25% remaining (~0.334 mg/L)3×t½ (42h): 12.5% remaining (~0.167 mg/L)4×t½ (56h): 6.3% remaining (~83.4 µg/L)5×t½ (70h): 3.1% remaining (~41.7 µg/L)
Plasma (PO)t½ Decay (14h)Effect Site (ke0)
  • 0×t½0h100% (1.34 mg/L)
  • 1×t½14h50% (0.668 mg/L)
  • 2×t½28h25% (0.334 mg/L)
  • 3×t½42h12.5% (0.167 mg/L)
  • 4×t½56h6.3% (83.4 µg/L)
  • 5×t½70h3.1% (41.7 µg/L)
Elimination t½14h (PO)
Rate Constant (ke)0.0495 h⁻¹
Time to Peak (Tmax)2.35h
Est. Peak (Cmax)1.34 mg/L
Clearance (CL)3.47 L/h
97% Washout (5×t½)70h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References